Interventional Radiology Imaging

What Is the Best Treatment for HCC with Vascular Invasion and Cirrhosis?

·
What Is the Best Treatment for HCC with Vascular Invasion and Cirrhosis?

A 64-year-old man with a history of cirrhosis secondary to nonalcoholic steatohepatitis presents for his six-month surveillance follow-up. A multiphasic contrast-enhanced MRI reveals a new 7 cm mass in the right hepatic lobe, consistent with LI-RADS 5 criteria for hepatocellular carcinoma (HCC). More concerning, however, is the presence of a non-occlusive tumor thrombus extending into the right portal vein. His liver function is compensated (Child-Pugh A), and his performance status is excellent. At the multidisciplinary tumor board, the central question is no longer diagnosis, but the optimal management strategy for this advanced-stage cancer. This article provides a clinical workflow for this exact scenario, guiding the decision between locoregional and systemic options. Based on the American College of Radiology (ACR) Appropriateness Criteria, both Systemic therapies and Transarterial radioembolization are rated Usually appropriate.

Who Fits This Clinical Scenario for HCC with Vascular Invasion?

This guidance applies to a specific and challenging patient population: those with confirmed hepatocellular carcinoma in the setting of underlying cirrhosis, where the tumor has demonstrated vascular invasion.

Inclusion criteria for this workflow:

  • Confirmed Diagnosis: Diagnosis of HCC is established, typically via characteristic imaging features (LI-RADS 5) or biopsy.
  • Underlying Cirrhosis: The patient has clinical, laboratory, or imaging evidence of cirrhosis, which significantly impacts liver function and treatment tolerance.
  • Vascular Invasion: There is clear radiographic evidence of tumor thrombus within a portal or hepatic vein. This can range from segmental branch invasion to involvement of the main portal vein.
  • Tumor Burden: The disease may be a single large tumor or multifocal, but is confined to the liver.

Exclusion criteria (patients who fit a different workflow):

  • No Vascular Invasion: Patients with solitary or multifocal HCC without vascular invasion fall into different Barcelona Clinic Liver Cancer (BCLC) stages. Small, solitary tumors may be candidates for curative-intent therapies like percutaneous ablation or surgical resection.
  • Extrahepatic Metastatic Disease: If the cancer has spread beyond the liver (e.g., to the lungs, bones, or lymph nodes), the patient has BCLC stage D disease. The management is palliative, and systemic therapy is the primary recommendation, with less consideration for liver-directed treatments.
  • Non-Cirrhotic Liver: A small subset of patients develops HCC without underlying cirrhosis. These individuals may have more robust liver function, potentially making them candidates for more aggressive surgical resection even with vascular invasion, a decision made by a specialized surgical team.

What Diagnoses Are You Working Up in This Scenario?

In this clinical scenario, the diagnosis of HCC is already established. The “workup” is not for a differential diagnosis of the liver mass itself, but rather for precise staging and risk stratification to determine the optimal therapeutic path. The key questions you are answering are about the extent of the disease and the patient’s ability to tolerate treatment.

Assessing the Extent of Vascular Invasion: The most critical initial step is to characterize the tumor thrombus. Is it confined to a segmental portal vein branch, or does it extend into a lobar or main portal vein? This distinction, best made with multiphasic CT or MRI, has profound prognostic implications and influences the choice between locoregional and systemic therapy. Invasion of the main portal vein is a particularly poor prognostic sign.

Evaluating Overall Liver Function: A patient’s underlying liver reserve is a primary determinant of treatment eligibility. This is formally assessed using the Child-Pugh score and MELD (Model for End-Stage Liver Disease) score. A patient with well-compensated cirrhosis (Child-Pugh A) can tolerate a wider range of therapies than a patient with decompensated cirrhosis (Child-Pugh B/C), who may be at high risk of treatment-induced liver failure.

Confirming Absence of Extrahepatic Disease: Before proceeding with any liver-directed therapy, it is mandatory to rule out distant metastases. This is typically accomplished with a CT scan of the chest. The presence of extrahepatic disease immediately upstages the patient and makes systemic therapy the standard of care.

Gauging Patient Performance Status: The patient’s overall health and functional capacity, often measured by the Eastern Cooperative Oncology Group (ECOG) performance status, is a crucial factor. A patient who is fully active (ECOG 0-1) is a better candidate for aggressive therapy than one who is symptomatic or bedridden (ECOG 2+).

Why Are Systemic Therapies and TARE ‘Usually Appropriate’ for HCC with Vascular Invasion?

The presence of vascular invasion signifies BCLC stage C (advanced) HCC, a point where curative-intent local therapies are no longer recommended. The treatment goal shifts to controlling disease, prolonging survival, and maintaining quality of life. The ACR panel designates two primary approaches as Usually appropriate for this scenario.

Systemic Therapies: This has become the backbone of treatment for advanced HCC. The modern armamentarium includes multi-tyrosine kinase inhibitors (TKIs) and, more prominently, immune checkpoint inhibitor (ICI) combinations. These agents have demonstrated significant survival benefits in large-scale clinical trials for patients with advanced HCC. Their key advantage is treating the entire patient, addressing not only the visible intrahepatic tumor and vascular thrombus but also any occult micrometastatic disease that is likely present. This is the standard first-line approach in many centers, especially for patients with main portal vein invasion or borderline performance status.

Transarterial Radioembolization (TARE): Also known as selective internal radiation therapy (SIRT), TARE is a sophisticated locoregional therapy. It involves the transarterial delivery of microspheres loaded with a radioisotope (typically Yttrium-90) directly into the arteries supplying the tumor. This allows for a very high dose of radiation to be delivered to the tumor and thrombus while sparing much of the surrounding normal liver parenchyma. TARE is often favored for patients with good liver function (Child-Pugh A) and disease confined to the liver. It can achieve excellent local tumor control and may be better tolerated than traditional chemoembolization in this setting.

Rationale for Lower-Rated Alternatives:

  • Transarterial Chemoembolization (TACE): Rated as May be appropriate, conventional TACE is less favored when significant portal vein invasion is present. The tumor thrombus impairs portal blood flow, making the liver more dependent on the hepatic artery. Occluding these arterial branches with TACE carries a substantial risk of inducing ischemic necrosis and acute liver failure.
  • Surgical Liver Resection / Liver Transplantation: Both are rated as Usually not appropriate. Vascular invasion is one of the strongest predictors of post-surgical recurrence and poor long-term outcomes. For transplantation, macrovascular invasion is a near-universal contraindication due to the extremely high risk of rapid and aggressive cancer recurrence in the new liver graft.

The choice between systemic therapy and TARE is complex and requires a multidisciplinary tumor board discussion involving hepatology, interventional radiology, medical oncology, and surgery to weigh the patient’s specific tumor characteristics, liver function, and overall health.

What’s Next After Treatment? Downstream Workflow

The management of advanced HCC is a dynamic process involving continuous monitoring and sequential therapies. The initial treatment choice dictates the subsequent surveillance and management pathway.

If the patient undergoes TARE:

  • Positive Response: Follow-up imaging (CT or MRI) is typically performed at 1-3 months to assess treatment response using modified RECIST (mRECIST) or similar criteria. A good response may be followed by continued observation or consideration of further locoregional therapy if new intrahepatic lesions appear. In some cases, a dramatic response (“downstaging”) could potentially reopen discussion for curative therapies, though this is uncommon.
  • Disease Progression: If the intrahepatic tumor progresses despite TARE, or if extrahepatic metastases develop, the patient should be transitioned to systemic therapy. The prior TARE treatment does not preclude the use of TKIs or immunotherapy.

If the patient starts Systemic Therapy:

  • Positive Response/Stable Disease: The patient will continue on systemic therapy as long as it is tolerated and effective. Regular follow-up imaging every 2-3 months is standard to monitor for response and progression.
  • Disease Progression: If the disease progresses on first-line systemic therapy, the next step is to consider second-line systemic agents. Several drugs are approved for use after initial therapy fails.
  • Intolerable Toxicity: If the patient cannot tolerate the side effects of the initial systemic regimen, a dose reduction, treatment holiday, or switch to an alternative systemic agent may be necessary.

In all cases, ongoing management of the patient’s underlying cirrhosis and portal hypertension is paramount to prevent decompensation and maintain quality of life.

Pitfalls to Avoid (and When to Get Help)

Navigating the care of patients with advanced HCC requires careful attention to detail to avoid common errors that can compromise outcomes.

  • Pitfall 1: Inadequate Staging: Failing to perform a high-quality, multiphasic CT or MRI of the abdomen and a CT of the chest can lead to understaging the disease. Missing the extent of vascular invasion or the presence of distant metastases can lead to offering inappropriate and ineffective locoregional therapies.
  • Pitfall 2: Misjudging Liver Function: Relying solely on a Child-Pugh score without a holistic clinical assessment can be misleading. Factors like ascites, encephalopathy, and nutritional status must be considered. Treating a patient with borderline or decompensated liver function can precipitate acute-on-chronic liver failure.
  • Pitfall 3: Delaying Multidisciplinary Discussion: This is not a scenario for a single practitioner to manage. The decision between TARE and systemic therapy is nuanced. An early and comprehensive discussion at a multidisciplinary tumor board is the standard of care and essential for optimal decision-making.

If a patient shows signs of clinical decompensation (worsening ascites, new-onset encephalopathy, variceal bleeding) at any point, escalate immediately to a hepatologist for management of their liver disease, as this may require pausing or modifying cancer-directed therapy.

Related ACR Topics and Tools

This article focuses on a single, complex clinical scenario. For a comprehensive overview of all variants and management pathways, or to explore the technical details of the recommended procedures, the following resources are essential. For breadth across all scenarios in Management of Liver Cancer, see our parent guide: Management of Liver Cancer: ACR Appropriateness Decoded.

Additional tools can help in applying these guidelines to your practice:

Frequently Asked Questions

Why is TACE (chemoembolization) only ‘May be appropriate’ when vascular invasion is present?

When a tumor invades the portal vein, it obstructs the liver’s primary blood supply. The liver compensates by increasing its reliance on the hepatic artery. TACE works by blocking these arteries to kill the tumor, which can critically compromise blood flow to the surrounding liver in this setting, carrying a high risk of causing liver failure. TARE (radioembolization) does not rely on this embolic effect and is therefore considered safer and more effective in this specific scenario.

Can a patient with portal vein invasion ever be a candidate for a liver transplant?

Generally, no. Macrovascular invasion is considered a contraindication for liver transplantation at most centers worldwide due to the very high risk of cancer recurrence in the new liver. However, some highly specialized centers may consider it within the context of a clinical trial, often after a patient has shown an exceptional response to other therapies (a process called ‘downstaging’).

How do you choose between systemic therapy and TARE if both are ‘Usually appropriate’?

This is a complex decision made by a multidisciplinary tumor board. Factors include the extent of vascular invasion (main vs. branch portal vein), the patient’s liver function (Child-Pugh score), tumor burden, patient performance status, and local institutional expertise. Often, TARE is favored for robust patients with disease confined to the liver, while systemic therapy is the standard for those with more extensive disease or borderline liver function.

Does the type of vascular invasion (portal vein vs. hepatic vein) change the recommendation?

While both represent advanced disease, portal vein invasion is more common and has a more direct impact on liver function and the safety of embolotherapies. Hepatic vein invasion is also a poor prognostic sign and similarly places the patient in an advanced stage where systemic therapy or TARE are the primary considerations. The core recommendation does not change, but the specific technical approach for TARE might be adjusted.

If a patient has a bland (non-tumor) portal vein thrombus and HCC, does this workflow still apply?

No, this workflow is specifically for malignant tumor thrombus. A bland thrombus is a separate clinical problem, often related to the underlying cirrhosis and portal hypertension. While it complicates management, it does not automatically upstage the cancer to BCLC stage C. A patient with a small HCC and a bland thrombus might still be a candidate for other therapies, and the management of the thrombus itself (e.g., with anticoagulation) would be a parallel goal.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026